Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
ACELYRIN, INC. - Common Stock
(NQ:
SLRN
)
2.270
UNCHANGED
Last Price
Updated: 4:00 PM EDT, May 20, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about ACELYRIN, INC. - Common Stock
< Previous
1
2
3
4
5
Next >
ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
May 13, 2025
From
ACELYRIN, INC.
Via
GlobeNewswire
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis
May 06, 2025
ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis
May 01, 2025
From
ACELYRIN, INC.
Via
GlobeNewswire
Alumis and ACELYRIN Announce Amended Merger Agreement
April 21, 2025
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN
April 16, 2025
From
Kahn Swick & Foti, LLC
Via
Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPTN, SLRN, AKYA, SHYF on Behalf of Shareholders
April 07, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan
March 13, 2025
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
March 04, 2025
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger
March 04, 2025
From
ACELYRIN, INC.
Via
GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVRO, TGI, PTMN, SLRN on Behalf of Shareholders
February 21, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
February 20, 2025
From
ACELYRIN, INC.
Via
GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IPG, SLRN, PTMN, HEES on Behalf of Shareholders
February 18, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PLYA, SLRN, NVRO, AMPS on Behalf of Shareholders
February 10, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN
February 10, 2025
From
Kahn Swick & Foti, LLC
Via
Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVRO, SLRN, TGI, PTMN on Behalf of Shareholders
February 10, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
SLRN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ACELYRIN, Inc. Is Fair to Shareholders
February 06, 2025
From
Halper Sadeh LLC
Via
Business Wire
Shareholder Alert: Ademi & Fruchter LLP investigates whether ACELYRIN, INC. is obtaining a Fair Price for its Public Shareholders
February 06, 2025
From
Ademi & Fruchter LLP
Via
Business Wire
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
February 06, 2025
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease
January 06, 2025
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab
January 02, 2025
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
December 10, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights
November 13, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024
November 06, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease
October 16, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024
September 19, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive
September 10, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN, INC. to Participate in Upcoming Investor Conferences
August 22, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results
August 13, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024
August 06, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024
June 05, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
